Nature Search

Sacituzumab tirumotecan in advanced non-small-cell lung cancer with or without EGFR mutations: phase 1/2 and phase 2 trials

In a phase 1/2 trial in patients with advanced non-small-cell lung cancer (NSCLC), followed by a phase 2 trial in an EGFR-mutant selected population, treatment with the TROP2-targeting antibody–drug conjugate sacituzumab tirumotecan led to encouraging clinical response rates, especially in patients with EGFR-mutant NSCLC, which was supported by mechanistic data.

Shen Zhao
Ying Cheng
Wenfeng Fang
Research10 Apr 2025
Nature Medicine

Volume: 31, P: 1976-1986
Garsorasib, a KRAS G12C inhibitor, with or without cetuximab, an EGFR antibody, in colorectal cancer cohorts of a phase II trial in advanced solid tumors with KRAS G12C mutation

Dan-Yun Ruan
Hao-Xiang Wu
Rui-Hua Xu
ResearchOpen Access17 Jun 2025
Signal Transduction and Targeted Therapy

Volume: 10, P: 1-9
Glecirasib in KRAS^G12C-mutated nonsmall-cell lung cancer: a phase 2b trial

In a single-arm phase 2b trial, glecirasib, an oral KRAS-G12C inhibitor, had an overall response rate of 47.9% in patients with locally advanced or metastatic KRAS^G12C-mutated nonsmall-cell lung cancer.

Yuankai Shi
Jian Fang
Zhiyue Rao
Research06 Jan 2025
Nature Medicine

Volume: 31, P: 894-900
Benmelstobart, anlotinib and chemotherapy in extensive-stage small-cell lung cancer: a randomized phase 3 trial

In this triple-arm, placebo-controlled phase 3 trial, first-line treatment of patients with extensive-stage small-cell lung cancer with the anti-PD-L1 benmelstobart, tyrosine kinase inhibitor anlotinib and chemotherapy (CT) showed improved survival outcomes compared with anlotinib and CT or CT alone.

Ying Cheng
Jianhua Chen
Runxiang Yang
ResearchOpen Access11 Jul 2024
Nature Medicine

Volume: 30, P: 2967-2976
Construction of angstrom-scale ion channels with versatile pore configurations and sizes by metal-organic frameworks

The fabrication of synthetic nanochannels for ion separation is challenging. Here, the authors synthesize angstrom-scale ion channels featuring one-dimensional to three-dimensional pore configurations by growing metal‒organic frameworks into nanochannels; the structure of the pore influences the ion transport performance.

Xingya Li
Gengping Jiang
Huacheng Zhang
ResearchOpen Access18 Jan 2023
Nature Communications

Volume: 14, P: 1-12
Inert Gas Deactivates Protein Activity by Aggregation

Lijuan Zhang
Yuebin Zhang
Haiping Fang
ResearchOpen Access31 Aug 2017
Scientific Reports

Volume: 7, P: 1-8
Interim survival analysis of the randomized phase III GEMSTONE-302 trial: sugemalimab or placebo plus chemotherapy as first-line treatment for metastatic NSCLC

Zhou et. al. report the interim results of the randomized phase III GEMSTONE-302 trial, showing the overall survival benefits of first-line treatment with the PD-L1 inhibitor sugemalimab versus placebo in combination with chemotherapy, in patients with NSCLC.

Caicun Zhou
Ziping Wang
Jason Yang
Research15 Jun 2023
Nature Cancer

Volume: 4, P: 860-871
Fast and selective fluoride ion conduction in sub-1-nanometer metal-organic framework channels

While biological fluoride ion channels display excellent F⁻ conductivity and selectivity, designing synthetic analogues remains highly challenging. Here the authors show that zirconium-based metal–organic frameworks with F⁻ binding sites and sub-1-nanometer channels exhibit ultrahigh F⁻ conductivity and selectivity.

Xingya Li
Huacheng Zhang
Huanting Wang
ResearchOpen Access11 Jun 2019
Nature Communications

Volume: 10, P: 1-12
Efficient metal ion sieving in rectifying subnanochannels enabled by metal–organic frameworks

Here, using an interfacial growth strategy, UiO-66 MOF nanocrystals are asymmetrically embedded into conical pores in a polymer membrane. These pores have a mono/divalent cation selectivity of 10³, which can be tuned by pH, and act as ionic rectifiers.

Jun Lu
Huacheng Zhang
Huanting Wang
Research09 Mar 2020
Nature Materials

Volume: 19, P: 767-774
Safety, pharmacokinetics and efficacy of HA121-28 in patients with advanced solid tumors and RET fusion-positive non-small-cell lung cancer: a multicenter, open-label, single-arm phase 1/2 trial

Dan-Yun Ruan
Wen-Wen Huang
Hongyun Zhao
ResearchOpen Access28 Feb 2025
Signal Transduction and Targeted Therapy

Volume: 10, P: 1-12
Publisher Correction: Interim survival analysis of the randomized phase III GEMSTONE-302 trial: sugemalimab or placebo plus chemotherapy as first-line treatment for metastatic NSCLC

Caicun Zhou
Ziping Wang
Jason Yang
Amendments and Corrections05 Jan 2024
Nature Cancer

Volume: 5, P: 209
A multicenter, randomized, double-blind, placebo-controlled phase 3 study of Socazolimab or placebo combined with carboplatin and etoposide in the first-line treatment of extensive-stage small cell lung cancer

Zhiwei Chen
Jianhua Chen
Xiaohui Yu
ResearchOpen Access13 Jan 2025
Signal Transduction and Targeted Therapy

Volume: 10, P: 1-8
Toripalimab plus chemotherapy for first line treatment of advanced non-small cell lung cancer (CHOICE-01): final OS and biomarker exploration of a randomized, double-blind, phase 3 trial

Jia Zhong
Kailun Fei
Jie Wang
ResearchOpen Access24 Dec 2024
Signal Transduction and Targeted Therapy

Volume: 9, P: 1-9
A novel gene fusion RUNX1/ZNF423 promotes leukemic relapse of NUP98-rearranged AML

Wenxin Du
Zhimei Xia
Meidan Ying
Research15 Sept 2023
Leukemia

Volume: 37, P: 2286-2291
Deneddylation of PML/RARα reconstructs functional PML nuclear bodies via orchestrating phase separation to eradicate APL

Xuejing Shao
Yingqian Chen
Meidan Ying
Research22 Feb 2022
Cell Death & Differentiation

Volume: 29, P: 1654-1668
A pivotal bridging study of lurbinectedin as second-line therapy in Chinese patients with small cell lung cancer

Ying Cheng
Chunjiao Wu
Fei Yu
ResearchOpen Access13 Feb 2024
Scientific Reports

Volume: 14, P: 1-10
Adiponectin protects the rats liver against chronic intermittent hypoxia induced injury through AMP-activated protein kinase pathway

Wenxiao Ding
Qiang Zhang
Xilong Zhang
ResearchOpen Access28 Sept 2016
Scientific Reports

Volume: 6, P: 1-12

Search

Sacituzumab tirumotecan in advanced non-small-cell lung cancer with or without EGFR mutations: phase 1/2 and phase 2 trials

Garsorasib, a KRAS G12C inhibitor, with or without cetuximab, an EGFR antibody, in colorectal cancer cohorts of a phase II trial in advanced solid tumors with KRAS G12C mutation

Glecirasib in KRAS^G12C-mutated nonsmall-cell lung cancer: a phase 2b trial

Benmelstobart, anlotinib and chemotherapy in extensive-stage small-cell lung cancer: a randomized phase 3 trial

Construction of angstrom-scale ion channels with versatile pore configurations and sizes by metal-organic frameworks

Inert Gas Deactivates Protein Activity by Aggregation

Interim survival analysis of the randomized phase III GEMSTONE-302 trial: sugemalimab or placebo plus chemotherapy as first-line treatment for metastatic NSCLC

Fast and selective fluoride ion conduction in sub-1-nanometer metal-organic framework channels

Efficient metal ion sieving in rectifying subnanochannels enabled by metal–organic frameworks

Safety, pharmacokinetics and efficacy of HA121-28 in patients with advanced solid tumors and RET fusion-positive non-small-cell lung cancer: a multicenter, open-label, single-arm phase 1/2 trial

Publisher Correction: Interim survival analysis of the randomized phase III GEMSTONE-302 trial: sugemalimab or placebo plus chemotherapy as first-line treatment for metastatic NSCLC

A multicenter, randomized, double-blind, placebo-controlled phase 3 study of Socazolimab or placebo combined with carboplatin and etoposide in the first-line treatment of extensive-stage small cell lung cancer

Toripalimab plus chemotherapy for first line treatment of advanced non-small cell lung cancer (CHOICE-01): final OS and biomarker exploration of a randomized, double-blind, phase 3 trial

A novel gene fusion RUNX1/ZNF423 promotes leukemic relapse of NUP98-rearranged AML

Deneddylation of PML/RARα reconstructs functional PML nuclear bodies via orchestrating phase separation to eradicate APL

A pivotal bridging study of lurbinectedin as second-line therapy in Chinese patients with small cell lung cancer

Adiponectin protects the rats liver against chronic intermittent hypoxia induced injury through AMP-activated protein kinase pathway

Search

Quick links

Search

Filter By:

Search

Quick links